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Abstract
In contrast to the many studies of the effects of individual amino acids (AAs)
on eating, no studies have compared the effects of different AAs on eating
and underlying preabsorptive gastrointestinal mechanisms. To compare the
effects of intraduodenal infusions of L-tryptophan (TRP), L-leucine (LEU), L-
phenylalanine (PHE) and L-glutamine (GLN) on appetite, gastrointestinal hor-
mone responses (including ghrelin, cholecystokinin (CCK), peptide YY (PYY)
and glucagon-like peptide-1 [GLP-1]), glycemia (glucagon, insulin and glu-
cose) and test meal size in healthy males, we retrospectively analyzed data
from four published independent, randomized, double-blind, placebo-con-
trolled studies of 90-min intraduodenal infusions of the individual AAs. The
designs of the studies were identical, except the dose of TRP (0.15 kcal/min)
was lower than that of the other AAs (0.45 kcal/min) because higher doses of
this AA were not well tolerated. TRP and LEU decreased intake more than
PHE (reductions relative to control, ~219  68, ~170  48 and
~12  57 kcal, respectively), and TRP decreased intake more than GLN
(~31  82 kcal). These effects of TRP and LEU versus GLN, but not versus
PHE, were paralleled by greater decreases in plasma ghrelin, and increases in
CCK, concentrations. TRP increased PYY more than GLN or LEU, but not
PHE. LEU increased PYY less than PHE. No significant differences were
detected for GLP-1. PHE increased glucagon more than TRP or LEU, and
increased insulin more than TRP. Under our experimental conditions,
intraduodenal TRP and LEU were more satiating than PHE and GLN. The
greater satiating efficacy of LEU versus PHE was significantly dissociated from
the effects of these AAs on PYY, while the greater satiating potency of TRP
versus PHE was significantly dissociated from the effects of these AAs on insu-
lin and glucagon. In contrast, ghrelin and CCK, and potentially other mecha-
nisms, including central sensing of individual AAs, appear to be stronger
candidate mechanisms for the relative satiating effects obtained.
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Introduction
There is evidence that protein inhibits eating and appetite
more than carbohydrate or fat in healthy-weight and
obese individuals (Batterham et al. 2003; Brennan et al.
2012), a notion reflected also in the protein leverage
hypothesis (Simpson and Raubenheimer 2005; Gietzen
and Aja 2012). The eating-inhibitory effects occur, depen-
dent on energy balance, both after acute administration,
for example, within single meals (Rolls et al. 1988; Batter-
ham et al. 2006; Brennan et al. 2012), and in individuals
adapted to high-protein diets (Due et al. 2004; Weigle
et al. 2005; Westerterp-Plantenga et al. 2009; Martens and
Westerterp-Plantenga 2014). In addition, protein is
increasingly recognized for its beneficial effect on post-
prandial glycemic control in type 2 diabetes (Ma et al.
2009) and its capacity to preserve muscle mass during
weight loss (Pasiakos et al. 2013). Accordingly, there is
increasing interest in the use of protein supplements and
high-protein diets in the management of obesity with and
without type 2 diabetes (Larsen et al. 2010).
A variety of mechanisms may contribute to the inhibi-
tory effects of protein on eating. Postabsorptive effects
include the thermic effect of protein (Westerterp-Plan-
tenga et al. 1999), increased intestinal gluconeogenesis
and associated glucose sensing in the portal vein
(Mithieux et al. 2005), and central sensing of absorbed
amino acids (AAs), a possibility originally proposed by
Mellinkoff as the aminostatic control of eating (Mellinkoff
et al. 1956). Preabsorptive effects may also contribute to
the satiating efficacy of protein. These include changes in
gastrointestinal (GI) motor function, in particular the rate
of gastric emptying, which affect the degree of gastric dis-
tension, and secretion of GI hormones, such as ghrelin,
cholecystokinin (CCK), glucagon-like-peptide (GLP-1),
and peptide tyrosine tyrosine (PYY), all of which are
thought to contribute to the control of eating (Steinert
et al. 2017).
The GI responses to proteins appear to be affected by
their AA compositions, although which protein type is
most satiating remains unclear (Hall et al. 2003; Ander-
son et al. 2004; Diepvens et al. 2008). For example, Hall
et al. (2003) reported in healthy-weight subjects that a
preload of whey protein, which is rich in branched-chain
AAs, decreased eating, increased plasma levels of CCK
and GLP-1, and slowed the initial rate of gastric emptying
substantially more than an isoenergetic preload of casein.
Similarly, administration of individual AAs appears to
lead to differential eating and GI responses. Oral loads
and intraduodenal (ID) infusions of L-tryptophan (TRP),
L-phenylalanine (PHE) or L-leucine (LEU) reduced eating
and increased plasma CCK in several studies (Ballinger
and Clark 1994; Carney et al. 1994; Edelbroek et al. 1994;
Steinert et al. 2014, 2015a), whereas no effects on eating
were detected in studies of oral or intragastric preloads of
L-proline (Nuttall et al. 2004), L-isoleucine (Nuttall et al.
2008; Ullrich et al. 2016) or L-lysine (Kalogeropoulou
et al. 2009). In addition, we (Chang et al. 2013; Steinert
et al. 2014, 2015a,b) and others (Greenfield et al. 2009)
reported apparently differential effects of oral loads and
ID infusions of AAs, including L-glutamine (GLN), on
plasma levels of GLP-1 and antropyloroduodenal motility.
In contrast to the several studies of the effects of different
proteins, however, none of the latter studies compared
the magnitude of effects of the different AAs. Therefore,
to better understand the relative effects of individual AAs
on eating, and to gain insights into the potential mecha-
nisms that may lead to differential satiating effects, we
compared the effects of premeal ID infusion of TRP,
LEU, PHE or GLN on appetite, GI-hormone responses,
and meal size (in kcal [1 kcal = 4.184 kJ]), using data
from identically-designed, randomized, double-blind, pla-
cebo-controlled tests that have in part been previously
published (Steinert et al. 2014, 2015a,b).
Materials and Methods
Subjects
Four groups of healthy, normal-weight men (mean  SD;
TRP study: n = 10, age (years): 26.6  8.6 (range 18–42),
BMI (kg/m2): 22.5  2.1 (range 18.7–24.7); LEU study:
n = 11, age: 24.9  6.9 (range 18–44), BMI: 21.9  1.6
(range 18.9–23.9); PHE study: n = 10, age: 23.6  6.2
(range 18–40), BMI: 22.6  2.1 (range 19.4–25.3); GLN
study: n = 9, age: 30.3  13.2 (range 19–48), BMI:
22.5  2.3 (range 18.5–25.3) were studied (Fig. S1). In
each study, the number of subjects was determined by
power calculations based on our previous studies of the
effects of ID glucose or fatty acids on food intake and GI
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motor and hormone responses (Feltrin et al. 2004; Pili-
chiewicz et al. 2007). Exclusion criteria were smoking,
consumption of >20 g of alcohol/day, any medical condi-
tion, chronic GI symptoms, and the use of medications
known to affect GI function or appetite. Once included,
participants were assigned to a treatment order, which
was generated by an online tool for balanced randomiza-
tion (www.randomization.com) and performed by a
research officer who was not involved in data analysis.
The study protocols were approved by the Royal Adelaide
Hospital Research Ethics Committee and carried out in
accordance with the Declaration of Helsinki. Each subject
provided informed, written consent prior to their
enrolment.
Study design and protocol
In each of the four studies, subjects were studied on three
occasions, each separated by 3-10 days, on which they
received, in randomized, double-blind fashion, 90-min ID
infusions of LEU, PHE, GLN (total loads of 3.3 or 9.9 g,
i.e., 0.15 or 0.45 kcal/min, or isovolemic control infu-
sions), or TRP (loads of 1.7 or 3.3 g, i.e., 0.075 or
0.15 kcal/min, or control). Only data collected in
response to the higher dose for each AA were included in
the current analysis. The LEU, PHE, and GLN loads were
based on a report that 10 g of PHE was well tolerated
and inhibited eating and stimulated plasma CCK in
healthy subjects (Ballinger and Clark 1994). The TRP
dose was based on a previous study in which 3 g of TRP
decreased hunger and slowed gastric emptying (Carney
et al. 1994), and on our own preliminary studies (Steinert
et al. 2014) in which ID infusion of 0.1 kcal/min TRP
was well tolerated, but infusions above 0.2 kcal/min led
to reports of nausea or dizziness. AA solutions were pre-
pared by dissolving crystalline AA (PureBulk, Roseburg,
OR), 118.3 mg CaCl2 9 2H2O and NaCl, to achieve iso-
tonic [300 mOsm] solutions in 405 mL distilled water.
The isotonic control solution contained 118.3 mg
CaCl2 9 2H2O and 4.6 g NaCl in 405 mL distilled water
for TRP, PHE, and GLN and, 124.8 mg CaCl2 9 2H2O
and 3.2 g NaCl in 428 mL distilled water for LEU, due to
the lower solubility of the latter. Solutions were adminis-
tered at a rate of 4.5 (TRP, PHE, GLN) or 4.75 (LEU)
mL/min. Solutions were prepared by a research officer
who was not involved in the performance of the study or
analysis of the data, and were covered to blind the study
subject and the investigators performing the studies.
Subjects were instructed to abstain from alcohol and
strenuous exercise for 24 h and were provided with a stan-
dardized meal (Beef Lasagna, McCain Food, Wendouree,
Victoria, Australia, total energy content: 1160 kcal) to be
consumed at 19:00 h on the evening before each visit.
Subjects then ate or drank nothing, except water, until they
arrived at the laboratory at 08:30 h the following day. On
arrival, each subject was intubated with a manometric
catheter (total length: 100 cm; Dentsleeve International,
Mui Scientific, Mississauga, Ontario, Canada) used for
monitoring antropyloroduodenal pressures and ID admin-
istration of the solutions (Steinert et al. 2014, 2015a,b).
The latter were infused through a side-hole located
~14.5 cm distal to the pylorus. An intravenous cannula was
placed into a right forearm vein for blood sampling. Once
the catheter was positioned correctly (Steinert et al. 2014,
2015a,b), during phase I of the interdigestive migrating
motor complex, baseline blood samples at t = 10 and
0 min were taken, and ID AA or control infusions were
given from 0 to 90 min. Blood samples were collected every
15 min from 0 to 90 min, and perceptions of appetite and
GI symptoms were evaluated at the same time points (Par-
ker et al. 2004). At t = 90 min, the infusion was terminated
and the catheter removed. Subjects were then offered a
standardized, cold, buffet-style test-meal, the composition
of which has been described in detail previously (Nair et al.
2009), and invited to consume as much food as they wished
until they felt comfortably full, for a maximum of 30 min
(t = 90 to 120 min). After completion of the meal, at
t = 120 min, a final blood sample was collected and a VAS
questionnaire administered. Subjects were then free to leave
the laboratory.
Measurements
Food intake and appetite and GI perceptions
Energy intake (kcal) during the meal was calculated from
the amount of food eaten (g), measured by weighing each
food item before presentation and at the end of the meal,
using commercial software (FoodWorks 7.0; Xyris Soft-
ware, Highgate Hill, Queensland, Australia). Perceptions
of fullness, hunger, prospective food consumption and
desire to eat, as well as nausea and bloating, were quanti-
fied using validated 100-mm visual analog scales (VAS)
questionnaires (Parker et al. 2004).
Blood glucose and plasma hormone
concentrations
Blood samples were collected into ice-chilled EDTA tubes.
Blood glucose was determined using a portable glucometer
(Medisense Precision QLD; Abbott Laboratories, Bedford,
MA). Plasma was separated by centrifugation at ~1830 g
for 15 min at 4°C within 15 min of collection and stored at
70°C until assayed. Plasma total ghrelin (pg/mL) was
measured by radioimmunoassay (Phoenix Pharmaceuticals,
Mountain View, CA). Intra- and inter-assay coefficients of
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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variation (CVs) were ~5% and 15%, respectively. The
detection limit was 44 pg/mL. Plasma CCK (pmol/L) was
measured by radioimmunoassay after ethanol extraction
using an adaptation of the method of Santangelo et al.
(1998). Intra- and inter-assay CVs were ~8% and 13%,
respectively. The detection limit was 1 pmol/L. Plasma
total GLP-1 (pmol/L) was measured by radioimmunoassay
(Millipore, Billerica, MA). Intra- and inter-assay CVs were
~5% and 7%, respectively. The detection limit was 3 pmol/
L. Plasma total PYY (pg/mL) was measured by radioim-
munoassay (Linco Research, St. Charles, MO). Intra- and
inter-assay CVs were ~5% and 7%, respectively. The detec-
tion limit was 10 pg/mL. Plasma insulin (mU/L) was mea-
sured by an ELISA assay (Mercodia, Uppsala, Sweden).
Intra- and inter-assay CVs were ~3% and 9%, respectively.
The detection limit was 1 mU/L. Plasma glucagon (pg/mL)
was measured by radioimmunoassay (Millipore). Intra-
and inter-assay CVs were ~3% and 6%, respectively, and
the detection limit was 20 pg/mL.
Data and statistical analysis
Baseline (“0”) values were calculated as means of values
obtained between t = 10 and 0 min. Incremental areas
under the curve (iAUCs) were calculated for each AA and
its control infusion under the profiles (t = 0 to 90 min)
of VAS scores, blood glucose and plasma hormone con-
centrations. For all parameters (except food intake), data
were then expressed as change in iAUC for each AA rela-
tive to control infusion. These delta iAUCs are presented
in the Results section.
Data were analyzed with SPSS software (version 19.0,
SPSS, Chicago, IL) using planned comparisons, which
better focuses statistical power on specific comparisons
of interest than does factorial ANOVA. Two-way analy-
ses of variance, with delta iAUCs as the first factor and
AA type as the second factor, were performed to gener-
ate experiment-wide residual errors, which were used to
compute standard errors of the difference (SED) and t-
tests, whose significances were determined using the
Bonferroni–Hochberg method (Hochberg 1988), with
minimum experiment-wide two-tailed alpha levels of
0.05. Experiment-wide SEDs were 64 kcal for meal size,
318 mm 9 min for prospective food consumption,
1594 pg/mL 9 min for ghrelin, 14 pmol/L 9 min for
CCK, 222 pmol/L 9 min for GLP-1, 716 pg/mL 9 min
for PYY, 9.5 mmol/L 9 min for blood glucose, 24 mU/
L 9 min for insulin and 318 pg/mL 9 min for gluca-
gon. Five comparisons were performed to test whether
GLN or PHE inhibit eating differently than TRP or
LEU, which each inhibited eating when tested individu-
ally (Steinert et al. 2014, 2015a), and whether TRP inhi-
bits eating differently than LEU: (1) GLN versus TRP,
(2) GLN versus LEU, (3) PHE versus TRP, (4) PHE ver-
sus LEU, and (5) TRP versus LEU. The GLN versus
PHE comparison was not done because neither of these
AA inhibited eating when tested individually. The same
five comparisons were done for all other measurements.
Data are presented as means  SEM.
Results
Appetite and GI perceptions
TRP (512  381 mm 9 min, relative to control infu-
sion) and PHE (634  356) each decreased delta iAUC
for prospective food consumption significantly more than
LEU (436  223; P < 0.05 and P < 0.01, respectively);
the difference between LEU and GLN (94  298) was not
significant (Fig. 1A). The planned comparisons failed to
reveal significant differences in the delta iAUCs for full-
ness, hunger, desire to eat, nausea or bloating during
TRP, LEU, PHE or GLN infusion (data not shown).
Energy intake
Both TRP (219  68 kcal) and LEU (170  48 kcal)
decreased energy intake more than PHE (12  57 kcal;
P < 0.05), and TRP decreased energy intake more than
GLN (31  82 kcal, P < 0.05) (Fig. 1B). The mean
reduction in energy intake appeared greater with LEU
than with GLN, but the difference was not significant.
Plasma ghrelin, CCK, GLP-1 and PYY
Individual time profiles for plasma ghrelin, CCK, GLP-1,
PYY, insulin, glucagon and blood glucose are shown in
Figures S2–S8. The results of the planned comparisons of
delta iAUCs are reported below.
Ghrelin
Both TRP (3524  2453 pg/mL 9 min) and LEU
(2842  1282) reduced plasma ghrelin delta iAUC sig-
nificantly more than GLN (2804  1954; P < 0.01 for
both), but the differences between TRP and PHE
(534  862) and between LEU and PHE were not sig-
nificant (Fig. 2A).
CCK
Both TRP (77  9 pmol/L 9 min) and LEU (65  9)
increased plasma CCK delta iAUCs more than GLN
(17  15; P < 0.01 for both), but the differences
between TRP and PHE (61  18) and between LEU and
PHE were not significant (Fig. 2B).
2017 | Vol. 5 | Iss. 21 | e13492
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GLP-1
None of the planned contrasts in GLP-1 delta iAUCs dur-
ing TRP (322  114 pmol/L 9 min), LEU
(147  194), PHE (139  204) or GLN (52  370)
infusion was significant (Fig. 2C).
PYY
TRP (2100  672 pg/mL 9 min) increased plasma PYY
delta iAUC more than LEU (621  445; P < 0.01) or
GLN (75  1175; P < 0.05), but not significantly more
Figure 2. Changes in plasma ghrelin (A), cholecystokinin (CCK) (B),
glucagon-like peptide-1 (GLP-1) (C) and peptide YY (PYY) (D) during
90-min intraduodenal infusions of L-tryptophan (TRP) at 0.15 kcal/
min, or L-leucine (LEU), L-phenylalanine (PHE) or L-glutamine (GLN) at
0.45 kcal/min. Data are changes from respective control infusions,
expressed as 90-min incremental areas under the curve (delta iAUCs),
means  SEM; n = 10 for TRP and PHE, n = 9 for GLN, and n = 11
for LEU. Data were analyzed using a planned comparison approach.
Two-way analyses of variance, with delta iAUCs as the first factor and
AA type as the second factor, were performed to generate
experiment-wide residual errors, which were used to compute
standard errors of the difference (SED) and t-tests, whose
significances were determined using the Bonferroni–Hochberg
method (Hochberg 1988), with minimum experiment-wide two-
tailed alpha levels of 0.05. Five comparisons were performed to test
whether GLN and PHE inhibit eating similarly to TRP and LEU and
whether TRP inhibits eating similarly to LEU: (1) TRP versus LEU, (2)
TRP versus GLN, (3) TRP versus PHE, (4) LEU versus GLN, and (5) LEU
versus PHE. *P < 0.05, **P < 0.01
Figure 1. Changes in (A) food intake at a buffet meal and (B)
premeal visual analog scale (VAS) ratings of prospective food
consumption (PFC) in response to 90-min intraduodenal infusions
of L-tryptophan (TRP) at 0.15 kcal/min, or L-leucine (LEU), L-
phenylalanine (PHE) or L-glutamine (GLN) at 0.45 kcal/min. Energy
intake data are changes from respective control infusions,
means  SEM; PFC data are 90-min incremental areas under the
curve relative to control (delta iAUCs); n = 10 for TRP and PHE,
n = 9 for GLN, and n = 11 for LEU. Data were analyzed using a
planned comparison approach. Two-way analyses of variance, with
delta iAUCs as the first factor and AA type as the second factor,
were performed to generate experiment-wide residual errors, which
were used to compute standard errors of the difference (SED) and
t-tests, whose significances were determined using the Bonferroni–
Hochberg method (Hochberg 1988), with minimum experiment-
wide two-tailed alpha levels of 0.05. Five comparisons were
performed to test whether GLN and PHE inhibit eating similarly to
TRP and LEU and whether TRP inhibits eating similarly to LEU: (1)
TRP versus LEU, (2) TRP versus GLN, (3) TRP versus PHE, (4) LEU
versus GLN, and (5) LEU versus PHE. *P < 0.05, **P < 0.01
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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than PHE (1209  50). PHE increased plasma PYY delta
iAUC more than LEU (P < 0.05). There was no signifi-
cant difference between LEU and GLN (Fig. 2D).
Blood glucose, plasma insulin, and plasma
glucagon
Blood glucose
None of the planned contrasts in blood glucose delta
iAUC during TRP (3.4  13.2 mmol/L 9 min), LEU
(10.6  6.3), PHE (3.4  8.8) or GLN (11.4  8.5)
infusion was significant (Fig. 3A).
Insulin
PHE (140  31 mU/L 9 min) increased plasma insulin
delta iAUC more than TRP (70  17; P < 0.05). None of
the other planned contrasts was significant (LEU and
GLN delta iAUCs were 118  17 and 57  29 mU/
L 9 min, respectively) (Fig. 3B).
Glucagon
PHE (2775  434 pg/mL 9 min) increased plasma glu-
cagon delta iAUC more than TRP (1144  270,
P < 0.01) or LEU (594  108; P < 0.01). None of the
other planned contrasts was significant (GLN was
378  399 pg/mL 9 min) (Fig. 3C).
Discussion
This retrospective study evaluated the relative effects of
ID infusions of four individual AAs on eating, subjec-
tive appetite and GI hormone responses in normal-
weight males. Given the increasing interest in the use
of protein supplements and high-protein diets in the
management of obesity and type 2 diabetes (Larsen
et al. 2010), and the phenomenon that physiological
responses to proteins appear to be affected by their AA
compositions (Hall et al. 2003; Anderson et al. 2004;
Diepvens et al. 2008), this is an important question.
Our analysis verified that, at least under the conditions
tested, these AAs have significantly different effects on
meal size in kcal, that is, behavioral satiation (Steinert
et al. 2017). TRP, despite being given at a lower dose,
reduced meal size significantly more than PHE or GLN,
and LEU reduced meal size more than PHE. In addi-
tion, we found several dissociations between the pat-
terns of significance of the AAs’ effect on eating and
their effects on GI hormonal responses that shed light
on mechanisms possibly underlying the differential eat-
ing-inhibitory effects.
The greater eating-inhibitory potency of TRP compared
with PHE or GLN is especially interesting, because the
TRP dose (0.15 kcal/min) was only one third of that of
PHE and GLN (0.45 kcal/min). Importantly, although
TRP reduced energy intake more than PHE, PHE
Figure 3. Changes in plasma insulin (A), glucagon (B) and blood
glucose (C) during 90-min intraduodenal infusions of L-tryptophan
(TRP) at 0.15 kcal/min, or L-leucine (LEU), L-phenylalanine (PHE) or L-
glutamine (GLN) at 0.45 kcal/min. Data are changes from
respective control infusions, expressed as 90-min incremental areas
under the curve (delta iAUCs), means  SEM; n = 10 for TRP and
PHE, n = 9 for GLN, and n = 11 for LEU. Data were analyzed using
a planned comparison approach. Two-way analyses of variance,
with delta iAUCs as the first factor and AA type as the second
factor, were performed to generate experiment-wide residual
errors, which were used to compute standard errors of the
difference (SED) and t-tests, whose significances were determined
using the Bonferroni–Hochberg method (Hochberg 1988), with
minimum experiment-wide two-tailed alpha levels of 0.05. Five
comparisons were performed to test whether GLN and PHE inhibit
eating similarly to TRP and LEU and whether TRP inhibits eating
similarly to LEU: (1) TRP versus LEU, (2) TRP versus GLN, (3) TRP
versus PHE, (4) LEU versus GLN, and (5) LEU versus PHE. *P < 0.05,
**P < 0.01
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increased glucagon and insulin delta iAUCs more than
TRP. Thus, the greater eating-inhibitory effect of TRP
than PHE was not related to premeal increases of gluca-
gon or insulin. With regard to the GI-hormonal effects,
we previously reported that this dose of ID TRP signifi-
cantly increased plasma concentrations of CCK, GLP-1
and PYY (Steinert et al. 2014). In the current analysis,
TRP reduced ghrelin delta iAUCs, and increased CCK
delta iAUC, more than GLN, and increased PYY delta
iAUC more than either GLN or LEU. Because CCK is a
well-established satiation signal (and PYY may be as well),
and ghrelin is regarded as a hunger signal (Steinert et al.
2017), it is possible that differential stimulation of these
hormones may contribute to the different meal size
effects, although any causal links remain to be established.
We previously also found an inverse correlation between
meal size and plasma TRP levels during ID TRP infusion
(Steinert et al. 2014), suggesting a postabsorptive aminos-
tatic contribution to the eating-inhibitory effect of TRP
(Frankland et al. 1956; Mellinkoff et al. 1956), possibly
related to increased synthesis of 5-hydroxy-tryptamine (5-
HT, serotonin), which is well known for its role in the
control of eating (Blundell 1977; Halford et al. 2005).
Finally, it is important to recognize that gut hormones
stimulated by TRP, including CCK and PYY, potently
slow gastric emptying (Steinert et al. 2017), and 5-HT is
a key controller of GI motor functions (Read and Gwee
1994), thus, gastric emptying, although not measured in
our study, may contribute to the eating-inhibitory effect
of TRP.
The superior satiating potency of LEU compared with
PHE was associated with significantly smaller PYY and
glucagon delta iAUCs. This clear dissociation indicates
that average premeal increases in these hormones were
not involved in the satiation effect of LEU. In addition,
the superior satiating potency of LEU compared with
PHE occurred in the absence of any significant differences
in ghrelin, CCK, GLP-1 or insulin delta iAUCs. Thus,
these data do not support roles for these hormones in the
differential satiating effects of LEU and PHE. It is impor-
tant to note, however, first, that the current analysis was
not sufficiently powered to permit statistical comparison
of temporal changes in hormone levels (shown in
Figs. S2–S8), and, second, that GI-hormonal satiation sig-
naling may involve paracrine or other local signaling
mechanisms (Steinert et al. 2017), not reflected in delta
iAUCs. These possibilities warrant further evaluation.
Finally, postabsorptive mechanisms may mediate LEU-
induced satiation. In support, we previously found that
plasma LEU concentrations increased substantially relative
to control following ID LEU infusion (Steinert et al.
2015a), and both hypothalamic (Cota et al. 2006; Mor-
rison et al. 2007) and brainstem (Blouet and Schwartz
2012) LEU sensitivity have been linked to the inhibition
of eating.
That PHE inhibited eating less than TRP, despite simi-
lar increases in plasma CCK, GLP-1, PYY and glucagon,
is surprising and does not support the general importance
of these hormones in the relative effects of these AAs on
eating. As mentioned above, it is important to note, how-
ever, that the current analysis was not sufficiently pow-
ered to permit statistical comparison of momentary
hormone levels (see Figs. S2–S8), which may contribute
to the AAs’ differential effects on appetite and eating.
Additional dissociations involving PHE were that PHE
increased plasma glucagon more than TRP or LEU and
increased plasma insulin more than TRP, although both
TRP and LEU reduced energy intake more than PHE.
This is surprising given the evidence that both glucagon
and insulin can contribute to the inhibition of eating in
humans or nonhuman primates in other test situations
(Woods et al. 1979; Geary et al. 1992). Again, however,
tests of glucagon and insulin levels at potentially critical
moments, such as at meal onset or meal end, would be
required to more fully investigate their potential contribu-
tions.
Interestingly, the differences in the eating-inhibitory
efficacies of AAs were not closely associated with the
appetite delta iAUCs. For example, LEU reduced meal
size markedly more, but reduced premeal prospective
consumption significantly less, than PHE. LEU also
reduced prospective food consumption less than TRP, but
these two AAs did not differ in their effects on eating.
Our analyses revealed no differences in the effects of AAs
on other appetite ratings, possibly because our study was
not powered to detect between-subjects differences (Flint
et al. 2000). It is also important to note that, although
appetite VAS are sensitive to experimental manipulations
and reproducible (Flint et al. 2000; Parker et al. 2004;
Stubbs et al. 2007), they have failed to predict meal size
under some conditions (Flint et al. 2000; Stubbs et al.
2007).
The effects of AAs on glycemic control are complex
and were not a primary focus of our studies. We previ-
ously found a small blood glucose-lowering, insulinotro-
pic effect of LEU and a small insulinotropic effect of TRP
(Steinert et al. 2014, 2015a), but did not find any differ-
ences in effects between AAs in the current study. How-
ever, we only investigated the differential effects of AAs
on “fasting” blood glucose. Determination of the effects
of AAs on meal-related glycemia, that is, using an experi-
mental design with concomitant administration of carbo-
hydrates, may have resulted in a different outcome, and
warrants further evaluation.
Our study has a number of limitations that require
consideration. (1) As outlined, this study was an analysis
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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of data from four separate studies, rather than one
prospective cross-over study encompassing all four AAs.
Although identically designed, TRP was given at a lower
dose (yet was substantially more satiating). (2) To what
extent our findings apply to more physiological condi-
tions under which foods high in specific AAs are ingested
is not known. (3) We ended infusions before the test
meals; infusions continued into the meal may have
revealed additional satiation effects. (4) We offered test
meals at a specific time, rather than when the subjects
were ready to eat; the latter design may have revealed
effects on postprandial satiety. (5) Our study was also not
powered to analyze absolute hormone levels at each mea-
surement time. We observed prompt secretion of CCK in
response to TRP and LEU within 30 min upon start of
the infusions (Steinert et al. 2014, 2015a), while GLP-1
secretion with TRP was delayed, with elevated concentra-
tions occurring between 75–90 min (Steinert et al. 2014).
Such differences may differentially affect food intake
(Steinert et al. 2017). (6) We did not analyze temporal
dynamics of changes in plasma AA concentrations, such
as relative rates of change, which would provide addi-
tional information on aminostatic controls of eating.
In conclusion, ID infusions of TRP (at 0.15 kcal/min),
LEU, PHE and GLN (all three at 0.45 kcal/min) produce
differential effects on food intake and GI and pancreatic
endocrine responses. The greater satiating efficacy of LEU
versus PHE was significantly dissociated from their effects
on PYY, while the greater satiating potency of TRP versus
PHE was significantly dissociated from their effects on
insulin and glucagon. In contrast, ghrelin and CCK, and
potentially other mechanisms, including neural sensing of
individual AAs, appear to be stronger candidate mecha-
nisms for the relative satiating effects obtained. This war-
rants evaluation in prospective studies.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Figure S1. Diagram of participant flow through the
studies.
Figure S2. Plasma ghrelin concentrations during 90-min
ID infusions of L-tryptophan (TRP) at 0.15 kcal/min, or
L-leucine (LEU), L-phenylalanine (PHE) or L-glutamine
(GLN) at 0.45 kcal/min or respective controls (A–D).
Figure S3. Plasma cholecystokinin (CCK) concentrations
during 90-min ID infusions of L-tryptophan (TRP) at
0.15 kcal/min, or L-leucine (LEU), L-phenylalanine (PHE)
or L-glutamine (GLN) at 0.45 kcal/min or respective con-
trols (A–D). For statistical comparisons, incremental areas
under the curve (iAUCs) were calculated for each AA and
its control infusion under the profiles (t = 0 to 90 min)
and data expressed as changes in iAUC for each AA rela-
tive to control infusion (see Fig. 2).
Figure S4. Plasma glucagon-like peptide-1 (GLP-1) con-
centrations during 90-min ID infusions of L-tryptophan
(TRP) at 0.15 kcal/min, or L-leucine (LEU), L-phenylala-
nine (PHE) or L-glutamine (GLN) at 0.45 kcal/min or
respective controls (A–D).
Figure S5. Peptide YY (PYY) concentrations during 90-
min ID infusions of L-tryptophan (TRP) at 0.15 kcal/min,
or L-leucine (LEU), L-phenylalanine (PHE) or L-glutamine
(GLN) at 0.45 kcal/min or respective controls (A–D).
Figure S6. Blood glucose concentrations during 90-min
ID infusions of L-tryptophan (TRP) at 0.15 kcal/min, or
L-leucine (LEU), L-phenylalanine (PHE) or L-glutamine
(GLN) at 0.45 kcal/min or respective controls (A–D).
Figure S7. Plasma insulin concentrations during 90-min
ID infusions of L-tryptophan (TRP) at 0.15 kcal/min, or
L-leucine (LEU), L-phenylalanine (PHE) or L-glutamine
(GLN) at 0.45 kcal/min or respective controls (A-D).
Figure S8. Plasma glucagon concentrations during 90-
min ID infusions of L-tryptophan (TRP) at 0.15 kcal/min,
or L-leucine (LEU), L-phenylalanine (PHE) or L-glutamine
(GLN) at 0.45 kcal/min or respective controls (A–D).
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